It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Depression is very common after stroke, causing multiple sequelae. We aimed to explore the efficacy of escitalopram for poststroke depression (PSD). PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials, Clinical trials. gov, Wan fang Data (Chinese), VIP (Chinese) and CNKI (Chinese) were retrieved from inception to May 2021. We recruited Randomized Controlled Trials (RCTs) which met the inclusion criteria in our study. The depression rating scores, the incidence of PSD, adverse events as well as functional outcomes were analyzed. 11 studies and 1374 participants were recruited in our work. The results were depicted: the reduction of depression rating scores was significant in the escitalopram groups and the standard mean difference (SMD) was − 1.25 (P < 0.001), 95% confidence interval (95% CI), − 1.82 to − 0.68; the risk ratio (RR) of the incidence of PSD was 0.52 (95% CI, 0.29 to 0.91; P = 0.007 < 0.05), which was significantly lower in the escitalopram groups; Escitalopram is safe for stroke patients; there was improvement of the motor function. However, in sensitivity analyses, the conclusions of the motor function and the incidence of drowsiness were altered. The study suggests that escitalopram has a potentially effective role compared with control groups and demonstrates escitalopram is safe. However, the results of the motor function and the incidence of drowsiness should be considered carefully and remain to be discussed in the future.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China (GRID:grid.412633.1) (ISNI:0000 0004 1799 0733)
2 Zhengzhou University, College of Physical Education (Based School), Zhengzhou, People’s Republic of China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846)
3 Zhengzhou University, Department of Basic Medicine, School of Nursing and Health, Zhengzhou, People’s Republic of China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846); Zhengzhou University of Industrial Technology, Zhengzhou, People’s Republic of China (GRID:grid.495491.4); Medical School of Huanghe Science and Technology University, Zhengzhou, People’s Republic of China (GRID:grid.459572.8) (ISNI:0000 0004 1759 2380)
4 Henan University of Chinese Medicine, Zhengzhou, People’s Republic of China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X)
5 Zhengzhou University, Department of Clinical Medicine, School of Nursing and Health, Zhengzhou, People’s Republic of China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846)
6 Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, People’s Republic of China (GRID:grid.460080.a)
7 Zhengzhou University, Department of Basic Medicine, School of Nursing and Health, Zhengzhou, People’s Republic of China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846)